Literature DB >> 22730271

Differentiating combined hepatocellular and cholangiocarcinoma from mass-forming intrahepatic cholangiocarcinoma using gadoxetic acid-enhanced MRI.

Jiyoung Hwang1, Young Kon Kim, Min Jung Park, Mi Hee Lee, Seong Hyun Kim, Won Jae Lee, Hyun Chul Rhim.   

Abstract

PURPOSE: To examine the differential features of combined hepatocellular and cholangiocarcinoma (HCC-CC) from mass-forming intrahepatic cholangiocarcinoma (ICC) on gadoxetic acid-enhanced MRI.
MATERIALS AND METHODS: Forty patients with pathologically proven combined HCC-CC (n = 20) and ICCs (n = 20) who had undergone gadoxetic acid-enhanced MRI were enrolled in this study. MR images were analyzed for the shape of lesions, hypo- or hyperintense areas on the T2-weighted image (T2WI), rim enhancement during early dynamic phases, and central enhancement with hypointense rim (target appearance) on the 10-min and 20-min hepatobiliary phase (HBP). The significance of these findings was determined by the χ(2) test.
RESULTS: Irregular shape and strong rim enhancement during early dynamic phases, and absence of target appearance on HBP favored combined HCC-CCs (P < 0.05). Lobulated shape, weak peripheral rim enhancement, and the presence of complete target appearance on the 10-min and 20-min HBP favored ICCs (P < 0.05). However, 10 CC-predominant type of combined HCC-CC showed complete or partial target appearance on 10-min HBP.
CONCLUSION: The shape of tumors, degree of rim enhancement during early dynamic phases, and target appearance on HBP were valuable for differentiating between combined HCC-CC and mass-forming ICC on gadoxetic acid-enhanced MRI.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22730271     DOI: 10.1002/jmri.23728

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  32 in total

1.  Differentiation of intrahepatic mass-forming cholangiocarcinoma from hepatocellular carcinoma on gadoxetic acid-enhanced liver MR imaging.

Authors:  Rihyeon Kim; Jeong Min Lee; Cheong-Il Shin; Eun Sun Lee; Jeong Hee Yoon; Ijin Joo; Seong Ho Kim; Inpyeong Hwang; Joon Koo Han; Byung Ihn Choi
Journal:  Eur Radiol       Date:  2015-09-15       Impact factor: 5.315

Review 2.  Combined hepatocellular cholangiocarcinoma: a case report and review of literature.

Authors:  Shailender Singh; Subhankar Chakraborty; Neelima Bonthu; Stanley Radio; Shahid M Hussain; Aaron Sasson
Journal:  Dig Dis Sci       Date:  2013-02-09       Impact factor: 3.199

3.  cHCC-CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation.

Authors:  Elizabeth Brunt; Shinichi Aishima; Pierre-Alain Clavien; Kathryn Fowler; Zachary Goodman; Gregory Gores; Annette Gouw; Alex Kagen; David Klimstra; Mina Komuta; Fukuo Kondo; Rebecca Miksad; Masayuki Nakano; Yasuni Nakanuma; Irene Ng; Valerie Paradis; Young Nyun Park; Alberto Quaglia; Massimo Roncalli; Tania Roskams; Michiie Sakamoto; Romil Saxena; Christine Sempoux; Claude Sirlin; Ashley Stueck; Swan Thung; W M S Tsui; Xin-Wei Wang; Aileen Wee; Hirohisa Yano; Matthew Yeh; Yoh Zen; Jessica Zucman-Rossi; Neil Theise
Journal:  Hepatology       Date:  2018-05-09       Impact factor: 17.425

4.  How to utilize LR-M features of the LI-RADS to improve the diagnosis of combined hepatocellular-cholangiocarcinoma on gadoxetate-enhanced MRI?

Authors:  Hong Seon Lee; Myeong-Jin Kim; Chansik An
Journal:  Eur Radiol       Date:  2018-12-14       Impact factor: 5.315

5.  Gadoxetic acid-enhanced MRI for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: can hypointensity on the late portal venous phase be used as an alternative to washout?

Authors:  Kyoung A Baek; Seung Soo Kim; Hyeong Cheol Shin; Jeong Ah Hwang; Seo-Youn Choi; Woong Hee Lee; Chan Ho Park; Hyoung Nam Lee; Nam Hun Heo
Journal:  Abdom Radiol (NY)       Date:  2020-09

Review 6.  The treatment of cholangiocarcinoma: a hepatologist's perspective.

Authors:  Kamran Qureshi; Randhir Jesudoss; Abdullah M S Al-Osaimi
Journal:  Curr Gastroenterol Rep       Date:  2014-10

7.  Management of combined hepatocellular-cholangiocarcinoma: a case report and literature review.

Authors:  Ming Chi; Kaidi Mikhitarian; Chanjuan Shi; Laura W Goff
Journal:  Gastrointest Cancer Res       Date:  2012-11

Review 8.  Cholangiocarcinoma.

Authors:  Nataliya Razumilava; Gregory J Gores
Journal:  Lancet       Date:  2014-02-26       Impact factor: 79.321

Review 9.  Magnetic resonance evaluations of biliary malignancy and condition at high-risk for biliary malignancy: Current status.

Authors:  Reiji Sugita
Journal:  World J Hepatol       Date:  2013-12-27

Review 10.  Evidence Supporting LI-RADS Major Features for CT- and MR Imaging-based Diagnosis of Hepatocellular Carcinoma: A Systematic Review.

Authors:  An Tang; Mustafa R Bashir; Michael T Corwin; Irene Cruite; Christoph F Dietrich; Richard K G Do; Eric C Ehman; Kathryn J Fowler; Hero K Hussain; Reena C Jha; Adib R Karam; Adrija Mamidipalli; Robert M Marks; Donald G Mitchell; Tara A Morgan; Michael A Ohliger; Amol Shah; Kim-Nhien Vu; Claude B Sirlin
Journal:  Radiology       Date:  2017-11-21       Impact factor: 11.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.